Frederic Guerard - 24 Jun 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Jun 2025, 18:25:13 UTC
Prior SEC filing
11 Jun 2025
Next SEC filing
15 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John Dunn, Attorney-in-Fact

Key filing fact

Frederic Guerard filed Form 4 for CalciMedica, Inc. (CALC) on 26 Jun 2025.

Key facts

  • This page summarizes Frederic Guerard's Form 4 filing for CalciMedica, Inc. (CALC).
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 26 Jun 2025, 18:25.

Change

  • Previous filing in this sequence was filed on 11 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001825009 Primary reporting owner

Guerard Frederic

Relationship
Director
Address
C/O CALCIMEDICA, INC., 505 COAST S. BLVD, #202, LA JOLLA
Signature
/s/ John Dunn, Attorney-in-Fact
Signature date
26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+10,000
Change %
Price
$0.000000
Shares after
10,000
Date
24 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$1.53
Footnotes
F1, F2
CALC transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+5,000
Change %
Price
$0.000000
Shares after
5,000
Date
24 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,000
Exercise price
$1.53
Footnotes
F1, F3
CALC transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+15,000
Change %
Price
$0.000000
Shares after
15,000
Date
24 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,000
Exercise price
$1.53
Footnotes
F1, F4
CALC transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+10,000
Change %
Price
$0.000000
Shares after
10,000
Date
24 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$1.65
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

Footnote F2

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

Footnote F3

Immediately exercisable.

Footnote F4

1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

Footnote F5

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .